Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Clinical treatment programs	$ 45	$ 36	$ 157	$ 114
Total revenues	45	36	157	114
Costs and expenses:
Production/cost of goods sold	306	252	923	1,078
Research and development	1,894	2,173	6,550	6,827
General and administrative	2,174	2,070	7,210	5,964
Total costs and expenses	4,374	4,495	14,683	13,869
Operating loss	(4,329)	(4,459)	(14,526)	(13,755)
Interest expense	(3)	(4)	(9)	(14)
Interest and other income	130	89	414	624
Other than temporary impairment loss on marketable securities	0	(800)	0	(800)
Gain from sale of income tax net operating losses	0	0	1,126	686
Redeemable warrants valuation adjustment	0	38	1	229
Net loss	(4,202)	(5,136)	(12,994)	(13,030)
Other Comprehensive Income (Loss):
Unrealized gain (loss) on marketable securities	(169)	197	0	(848)
Reclassification adjustments for impairment losses included in net loss	0	800	0	800
Net comprehensive loss	$ (4,371)	$ (4,139)	$ (12,994)	$ (13,078)
Basic and diluted loss per share (usd per share)	$ (0.02)	$ (0.03)	$ (0.07)	$ (0.08)
Weighted average shares outstanding, basic and diluted (shares)	190,677,576	167,389,685	184,434,475	167,135,111